Perioperative pain, analgesics and cancer-related outcomes: where do we stand?

Pain Manag. 2022 Mar;12(2):229-242. doi: 10.2217/pmt-2021-0070. Epub 2021 Oct 12.

Abstract

Cancer-related pain is one of the most common and debilitating symptoms among cancer patients. Undertreated cancer-related pain interferes with daily activities and increases morbidity and mortality. While opioids continue to play an essential role in treating moderate to severe cancer-related pain, they are associated with many adverse effects including misuse. While preclinical and retrospective studies have shown a negative association between opioid use and cancer outcomes, randomized control trials demonstrate that opioid use does not influence cancer recurrence. Additionally, analgesics and adjuvants used for perioperatively or chronic pain control are unlikely to improve oncological outcomes. This article focuses on the pharmacological management of cancer-related pain and offers an overview regarding the use of these medications perioperatively and the cancer outcomes.

Keywords: analgesia; oncology; opioids; pain; postoperative pain.

Publication types

  • Review

MeSH terms

  • Analgesics / therapeutic use
  • Analgesics, Opioid / adverse effects
  • Humans
  • Neoplasms* / complications
  • Pain, Postoperative* / drug therapy
  • Retrospective Studies

Substances

  • Analgesics
  • Analgesics, Opioid